Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00038168 · ClinicalTrials.gov registry record · Phase 1
Intravenous Estramustine With Taxol in Hormone Refractory Prostate Adenocarcinoma
A Phase 1 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 14
- Enrollment target
NCT00038168: Completed Phase 1 study, sponsored by M.D. Anderson Cancer Center.
NCT00038168 is a Phase 1 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 14 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00038168, a Phase 1 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 14 participants
- Enrollment target
Study Summary
Phase I: The goal of this clinical research study is to find the highest dose of estramustine phosphate administered intravenously in combination with a fixed dose of Taxol (paclitaxel) that can be given safely to participants with prostate cancer who have failed to further benefit from hormone treatment. Phase II: The goal of this clinical research study is to find out if the combination of the drugs estramustine phosphate and paclitaxel will shrink or control prostate cancer that has not responded to hormone treatment. A second goal is to find out if the side effects of these drugs can be reversed. The safety of these drugs will also be studied.
Interventions
- DRUG Taxol
- DRUG Estramustine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2000-06 |
| Est. Completion | 2003-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00038168
The ClinicalTrials.gov registry entry for NCT00038168 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Taxol is the first listed.
NCT00038168 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00038168 about?
NCT00038168 is a clinical study titled "Intravenous Estramustine With Taxol in Hormone Refractory Prostate Adenocarcinoma". Phase I: The goal of this clinical research study is to find the highest dose of estramustine phosphate administered intravenously in combination with a fixed dose of Taxol (paclitaxel) that can be given safely to participants with prostate cancer who have failed to further benefit from hormone trea...
What is the current status of trial NCT00038168?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2000-06. Estimated completion is 2003-01.
What interventions are being tested in trial NCT00038168?
The interventions under investigation include: Taxol (DRUG), Estramustine (DRUG).
Who is sponsoring clinical trial NCT00038168?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.